Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease
3 de fevereiro de 2017 atualizado por: Pfizer
A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson's Disease And Motor Fluctuations
This study will be an open label, dose escalation study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated daily quaque die (QD) doses given over 21 days (Day 3 to Day 23) to sequential cohorts of subjects with Parkinson's disease.
Each cohort will have 2 study periods.
For each cohort, subjects will enter Period 1 and if they meet criteria, approximately 12 subjects will be enrolled into Period 2 and dosed with PF 06649751.
Based on results observed in a previous study, Cohorts 1 and 2 will not be conducted.
Cohorts 3 - 6 will test doses uptitrated to 5 mg, 15 mg and 25 mg QD.
Doses may be modified based on emerging safety, tolerability and PK data, but the maximum daily dose that will be given in any cohort will have PK predictions at steady state that are anticipated to be below toxicokinetic limits.
An option for down titration to the previous dose level is available should the investigator consider that an AE is intolerable.
Following down titration, a single up titration to the next dose level may be attempted if the subject remains symptom free for at least 48 hrs.
Safety, tolerability and PK data of Cohort 3 will be reviewed prior to initiating the dosing in Cohorts 4 and 5. Available safety, tolerability and PK data up to Day 24 of at least 5 subjects from Cohorts 4 will be reviewed prior to initiating the dosing in Cohort 6.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
50
Estágio
- Fase 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Brussels, Bélgica, B-1070
- Pfizer Clinical Research Unit
-
-
-
-
California
-
Fountain Valley, California, Estados Unidos, 92708
- The Parkinson's and Movement Disorder Institute
-
Fountain Valley, California, Estados Unidos, 92708
- Orange Coast Memorial Medical Center
-
Long Beach, California, Estados Unidos, 90806
- Collaborative Neuroscience Network, LLC
-
-
Colorado
-
Englewood, Colorado, Estados Unidos, 80113
- Rocky Mountain Movement Disorders Center
-
Lakewood, Colorado, Estados Unidos, 80228
- Davita Clinical Research Center
-
-
Florida
-
Hallandale Beach, Florida, Estados Unidos, 33009
- MD Clinical
-
Orlando, Florida, Estados Unidos, 32806
- Compass Research, LLC
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30331
- Atlanta Center for Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital -- FOR DRUG SHIPMENT ONLY
-
-
Michigan
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Quest Research Institute
-
-
New Jersey
-
Marlton, New Jersey, Estados Unidos, 08053
- PRA International
-
-
North Carolina
-
Raleigh, North Carolina, Estados Unidos, 27612
- Carolina Phase I Research, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73112
- Lynn Health Science Institute
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75231
- Neurology Consultants of Dallas, PA
-
Dallas, Texas, Estados Unidos, 75231
- Walnut Hill Medical Center
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
30 anos a 80 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Clinical diagnosis of idiopathic Parkinson's Disease with at least 2 out of 3 cardinal characteristics (tremor, rigidity, bradykinesia)
- Mini-Mental State Examination (MMSE) ≥ 25
- Hoehn & Yahr Stage I-III inclusive
- Documented history of end of L-Dopa wearing OFF
- Cohort 5 only: History of dyskinesia following L-Dopa dosing and Score of at least 2 on Part IV, item 4.2 (functional impact of dyskinesia) of the MDS-UPDRS
Exclusion Criteria:
- Atypical/secondary parkinsonism
- History of surgical intervention for Parkinson's Disease
- Dementia/cognitive impairment that can interfere with study assessments
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Não randomizado
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort 3
Titration of PF-06649751 up to 5 mg QD
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
|
Experimental: Cohort 4
Titration of PF-06649751 up to 15 mg QD
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
|
Experimental: Cohort 5
Titration of PF-06649751 up to 15 mg QDi n subjects with Levodopa-induced dyskinesias (LID)
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
|
Experimental: Cohort 6
Titration of PF-0649751 up to 25 mg QD
|
Oral daily doses titrated up to 5mg QD
Oral daily doses titrated up to 15 mg QD
Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
Oral daily doses titrated up to 25 mg QD
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Prazo: Baseline (Day 1) up to Day 30
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent were events between first dose of study drug to the end of study (up to Day 30) that were absent before treatment or that worsened relative to pre-treatment state.
AEs included both serious and non-serious adverse events.
|
Baseline (Day 1) up to Day 30
|
|
Number of Participants With Laboratory Test Abnormalities
Prazo: Baseline up to Day 30
|
Criteria for laboratory abnormalities: Hemoglobin (Hgb),hematocrit, red blood cell(RBC) count: less than(<)0.8*lower
limit of normal(LLN),mean corpuscular Hgb, mean corpuscular volume, mean corpuscular Hgb concentration:<0.9*LLN,
greater than (>)1.1*upper
limit of normal(ULN),platelet:<0.5*LLN,>1.75*ULN,lymphocyte,neutrophil:<0.8*LLN,
>1.2*ULN, basophil, eosinophil, monocyte:>1.2*ULN,
WBC:<0.6*LLN,
>1.5*ULN;total bilirubin>1.5*ULN,
aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase:>3.0*ULN,total
protein,albumin:<0.8*LLN,>1.2*ULN;blood
urea nitrogen,creatinine:>1.3*ULN, uric acid>1.2*ULN;sodium<0.95*LLN,>1.05*ULN,potassium,chloride,calcium,bicarbonate:<0.9*LLN,>1.1*ULN;glucose<0.6*LLN,>1.5*ULN,urine
pH:<4.5, >8; urine: WBC, RBC greater than or equal to (>=)20/high performance field, bacteria: >20; urobilinogen, urine: glucose, ketone, protein, Hgb, nitrite, leukocyte esterase, bilirubin: >=1.
|
Baseline up to Day 30
|
|
Number of Participants With Vital Sign Abnormalities
Prazo: Baseline up to Day 30
|
Criteria for vital sign abnormality included supine pulse rate of <40 beats per minute (bpm) or >120 bpm, standing pulse rate of <40 bpm or >140 bpm, supine and standing systolic blood pressure (SBP) <90 millimeter of mercury (mmHg), supine and standing diastolic blood pressure (DBP) <50 mmHg, supine and standing SBP of >=30 mmHg maximum (max.)
increase from baseline (IFB) and and decrease from baseline (DFB) in same posture, supine and Standing DBP of >=20 mmHg max.
increase and decrease from baseline in same posture.
Categories in which there was atleast 1 abnormality are reported in this outcome measure.
|
Baseline up to Day 30
|
|
Number of Participants With Electrocardiogram (ECG) Abnormalities
Prazo: Baseline up to Day 30
|
Criteria for ECG abnormalities: maximum PR interval >=300 milliseconds (msec) and maximum increase PR interval increase from baseline (IFB): percent change (Pctchg) >=25 percent (%) for baseline value of >200 msec and Pctchg>=50% for baseline value of <=200 msec for PR interval, maximum QRS interval >=140 msec and a maximum IFB: Pctchg>=50%, maximum QTCF interval (Fridericia's Correction) of 450 msec to <480 msec, 480 msec to <500 msec or >=500 msec and a maximum change of <=30change<60 or >=60 msec from baseline.
|
Baseline up to Day 30
|
|
Number of Participants With Clinically Significant Change From Baseline in Physical Examination Findings
Prazo: Baseline up to Day 30
|
Physical examination included examination of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems.
The examination assessed the participants for any potential changes in general appearance, the respiratory and cardiovascular systems, as well as towards participant reported symptoms.
Findings were considered to be clinically significant based on investigator's decision.
|
Baseline up to Day 30
|
|
Number of Participants With Clinically Significant Neurological Examination Abnormality
Prazo: Baseline up to Day 30
|
The complete or full neurological examination included assessment of the cranial nerves; muscle strength, tone, cortical drift, abnormal movements; deep tendon reflexes; sensory exam, coordination, gait and station.
Higher cortical and motor function was considered part of the complete neurological exam.
Findings were considered abnormal as confirmed by a certified neurologist.
|
Baseline up to Day 30
|
|
Number of Participants With Categorical Scores on The Columbia Suicide Severity Rating Scale (C-SSRS)
Prazo: Baseline up to Day 30
|
The C-SSRS was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior.
C-SSRS assessed whether participant experienced any of the following 1: completed suicide, 2: suicide attempt (response of "yes" on "actual attempt"), 3: preparatory acts toward imminent suicidal behavior ("yes" on "aborted attempt", "interrupted attempt", "preparatory acts or behavior"), 4: any suicidal behavior or ideation, suicidal ideation ("yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent"), 7: self-injurious behavior, no suicidal intent ("yes" on "has participant engaged in non-suicidal self-injurious behavior").
|
Baseline up to Day 30
|
|
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 13
Prazo: Baseline, Day 13
|
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia.
"ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness.
"ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia.
"OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
|
Baseline, Day 13
|
|
Change From Baseline in Parkinson's Disease Diary For Participants With Motor Fluctuations at Day 20
Prazo: Baseline, Day 20
|
According to Parkinson's disease diaries of participants "OFF" time was a time period when the medication no longer providing benefit with regard to mobility, slowness, and stiffness and participants experienced relatively poor overall function with worsening of tremor, rigidity, balance, or bradykinesia.
"ON" time was a time period when medication was providing benefit with regard to mobility, slowness, and stiffness.
"ON" time was classified as associated with or without troublesome dyskinesia (TD) that interfere with activities of daily living and with or without dyskinesia.
"OFF" time and "ON" time with TD were generally considered to be "bad time" with regard to motor function, whereas "ON" time without dyskinesia (WD) and with non- troublesome dyskinesia (NTD) were generally considered to be "good time".
|
Baseline, Day 20
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Maximum Observed Plasma Concentration (Cmax) of L-Dopa
Prazo: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of L-Dopa
Prazo: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
|
Apparent Clearance (CL/F) of L-Dopa
Prazo: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Terminal Half-Life (t1/2) of L-Dopa
Prazo: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Terminal half-life is the time measured for the plasma concentration of drug to decrease by one half.
It was calculated as dividing the natural logarithm to the base e (Log e)*2/k el, where k el is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Area Under the Curve From Time Zero Extrapolated to Infinite Time of L-Dopa
Prazo: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
AUC (0 - inf)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - inf).
It is obtained from AUC (0 - t) plus AUC (t - inf).
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration of L-Dopa
Prazo: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (C last).
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Apparent Volume of Distribution (Vz/F) of L-Dopa
Prazo: Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
|
Pre-dose, 0.5, 1, 2, 4 and 8 hours post-dose on Day 1
|
|
Maximum Observed Plasma Concentration (Cmax) of PF-06649751
Prazo: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06649751
Prazo: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
|
Apparent Clearance (CL/F) of PF-06649751
Prazo: Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 22
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 22
|
|
Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751
Prazo: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
Minimum Observed Plasma Trough Concentration (Cmin) of PF-06649751
Prazo: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
|
|
Ratio of Accumulation for Area Under the Curve From Time Zero to End of Dosing Interval of PF-06649751
Prazo: Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Rac was obtained from AUCtau after last dose divided by AUCtau after first dose, where AUC(tau) = Area under the concentration curve from time zero to end of dosing interval (AUCtau), where dosing interval was 12 hours.
|
Pre-dose on Day 3, 4, 8, 11, 14, 17, 20, Pre-dose, 0.5, 1, 1.5, 2, 4, 8 and 12 hour post-dose on Day 7, 13, 22
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de outubro de 2014
Conclusão Primária (Real)
1 de março de 2016
Conclusão do estudo (Real)
1 de março de 2016
Datas de inscrição no estudo
Enviado pela primeira vez
15 de agosto de 2014
Enviado pela primeira vez que atendeu aos critérios de CQ
21 de agosto de 2014
Primeira postagem (Estimativa)
25 de agosto de 2014
Atualizações de registro de estudo
Última Atualização Postada (Real)
27 de março de 2017
Última atualização enviada que atendeu aos critérios de controle de qualidade
3 de fevereiro de 2017
Última verificação
1 de dezembro de 2016
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- B7601005
- 2014-003472-22 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .